# Verve Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/verve-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.vervetx.com
- Total disclosed funding: $216M
- Latest round: Series B (Jan 14, 2021)
- Investors on record: 14

## About

Founded in 2018 and based in Massachusetts, US, Verve Therapeutics, Inc. is a biotechnology company that develops therapies for cardiovascular diseases (CVD) with gene editing medicines. The company treats CVD that collectively refers to diseases of the heart and the blood, diagnosed as atherosclerotic cardiovascular disease (ASCVD) or cardiomyopathy, among others. The firm was founded by Burt Adelman, J. Keith Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho. As of 2021, the company is chaired by Sekar Kathiresan as CEO. 
In 2020, Verve Therapeutics, Inc. raised USD 63 million in Series A2 funding led by returning investor GV. In 2021, Verve Therapeutics, Inc. raised USD 94 million in Series B funding co-led by returning investors Casdin Capital and Wellington Management. In June 2021, Verve Therapeutics, Inc. raised USD 266.68 million in an IPO, selling 14.04 million shares at USD 19 per share on the Nasdaq under the ticker symbol, VERV.

Verve Therapeutics develops medicines that involve making edits in adult cells, which are not passed onto the offspring. Verve’s lead product candidate is Verve-101- a single-course in vivo liver gene-editing treatment for patients with HeFH (Heterozygous Familial Hypercholesterolemia). Verve-101 utilizes LNP-mediated delivery and targets the PCSK9 and ANGPTL3 genes that are responsible for lowering blood lipids. 

Verve Therapeutics, Inc. plans on utilizing the Series A2 funding to advance its lead program through IND-enabling studies and fuel follow-on pipeline programs and Series B funding to advance its pipeline of gene editing medicines, led by VERVE-101, and further extend its scientific and technical leadership.

## Funding rounds

- Series B, Jan 14, 2021, $94M — Novo Holdings, Wellington Management, Janus Henderson Investors, GV, Redmile Group, Casdin Capital, RA Capital Management, Rock Springs Capital, Cormorant Asset Management, Biomatics Capital Partners, Surveyor Capital, Logos Capital
- Series A, Apr 9, 2020, $63M — ARCH Venture Partners, F-Prime Capital, Wellington Management, GV, Casdin Capital, Biomatics Capital Partners
- Series A, May 7, 2019, $59M — ARCH Venture Partners, F-Prime Capital, GV, Biomatics Capital Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Biomatics Capital Partners (https://capitalatlas.ai/funds/biomatics-capital-partners) — Series A, Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A, Series B
- Novo Holdings — Series B
- Janus Henderson Investors — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Rock Springs Capital — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Surveyor Capital — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B